Provention Bio - PRVB Stock Forecast, Price & News

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Analysts Set New Price Targets

Several analysts recently commented on PRVB shares. HC Wainwright cut their price objective on shares of Provention Bio from $25.00 to $18.00 and set a "buy" rating on the stock in a research report on Monday, July 11th. Chardan Capital cut their price objective on shares of Provention Bio from $22.50 to $21.00 and set a "buy" rating on the stock in a research report on Friday, August 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average target price of $18.33.

Provention Bio Price Performance

PRVB traded up $0.30 during midday trading on Friday, hitting $5.58. 3,714 shares of the company traded hands, compared to its average volume of 606,308. The company's 50-day moving average is $4.14 and its 200 day moving average is $5.19. Provention Bio has a 52 week low of $3.18 and a 52 week high of $8.04.

Provention Bio (NASDAQ:PRVB - Get Rating) last posted its earnings results on Thursday, August 4th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.03. The business had revenue of $0.75 million for the quarter, compared to analysts' expectations of $0.80 million. Provention Bio had a negative net margin of 3,840.68% and a negative return on equity of 100.07%. During the same quarter in the prior year, the business earned ($0.46) EPS. As a group, analysts predict that Provention Bio will post -1.83 EPS for the current year.